Summary
OMER Chart
Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster
Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros faces a significant cash burn, with only $52.5 million in cash as of March 2025. The company's cash runway is dangerously short, likely lasting only until late summer 2025, necessitating urgent financial action.
Omeros Corporation Reports First Quarter 2025 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At March 31, 2025, we had $52.4 million of cash and short-term investments available for operations and debt servicing, a decrease.
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted.
Omeros Corporation Dividends
Omeros Corporation Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Jun 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Jun 2024 Date | | - Cons. EPS | - EPS |
Omeros Corporation (OMER) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Omeros Corporation ever had a stock split?
Omeros Corporation Profile
| Biotechnology Industry | Healthcare Sector | Dr. Gregory A. Demopulos M.D. CEO | NASDAQ (NMS) Exchange | 682143102 Cusip |
| US Country | 202 Employees | - Last Dividend | - Last Split | 8 Oct 2009 IPO Date |
Overview
Omeros Corporation is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic products for a wide range of medical disorders. Founded in 1994 and based in Seattle, Washington, the company focuses on delivering innovative treatments for immunologic diseases, cancers, and conditions related to addiction and compulsive disorders. By targeting small-molecule and protein therapeutics, and specializing in orphan indications, Omeros is dedicated to addressing unmet medical needs, particularly in areas where treatment options are limited or non-existent.
Products and Services
- Narsoplimab (OMS721/MASP-2)
A pivotal clinical trial has been completed for Narsoplimab, a therapeutic candidate aimed at treating hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA). Additionally, it is undergoing a Phase III clinical trial for patients with immunoglobulin A nephropathy (IgAN) and a Phase II clinical trial to assess its efficacy in treating COVID-19.
- OMS1029
This long-acting, second-generation antibody is in Phase I clinical trials. It targets lectin pathway disorders, showcasing Omeros' commitment to addressing areas with significant unmet medical needs.
- OMS906
Currently, OMS906 has completed Phase II clinical trials. This product candidate is designed for the treatment of Paroxysmal nocturnal hemoglobinuria (PNH), complement 3 glomerulopathy (C3G), and other disorders associated with the alternative pathway of the complement system.
- OMS527
In Phase I clinical trials, OMS527 is being developed for the treatment of addictions and compulsive disorders, alongside movement disorders, demonstrating Omeros' foray into neurological conditions with significant impact on public health.
- Preclinical Development Programs
The company is also pursuing several ambitious preclinical development programs. These include MASP-2, targeting lectin pathway disorders; MASP-3 small-molecule inhibitors aimed at alternative pathway disorders; and a diverse array of immunotherapies such as Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for various cancers. These cutting-edge scientific endeavors highlight Omeros Corporation's dedication to pioneering treatments for complex conditions and diseases.
Contact Information
